If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine) injection
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the Basaglar® (insulin glargine injection) dose for pediatric patients?
When transitioning pediatric patients, aged 6 to 15 years with type 1 diabetes mellitus, to Basaglar, the dosage recommendation is the same as that described for adults.
Basaglar Dosage for Pediatric Patients
When transitioning pediatric patients, aged 6 to 15 years with type 1 diabetes mellitus, to Basaglar® (insulin glargine injection) 100 units/mL, the dosage recommendation is the same as that described for adults. As in adults, the dosage of Basaglar must be individualized in these pediatric patients based on
- metabolic needs, and
- frequent monitoring of blood glucose concentrations.1
The efficacy and safety of Basaglar have not been established for the treatment of pediatric patients
- younger than 6 years with type 1 diabetes mellitus, or
- with type 2 diabetes mellitus.1
Enclosed Prescribing Information
1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Date of Last Review: April 14, 2021